FOLLOW US

Express Scripts agreed Wednesday to what the Federal Trade Commission described as a “landmark settlement,” committing to sweeping revisions in how it structures drug formularies — and sidestepping a high-profile case that accused the nation’s three largest pharmacy benefit managers of driving up insulin prices through rebate tactics.

The agreement marks a dramatic pivot in a fight that has cast pharmacy benefit managers, or PBMs, as middlemen under the microscope. While Express Scripts exits the FTC’s in-house case, proceedings remain active against rival giants Caremark Rx and OptumRx.

A Decade of Promised Savings

The FTC said the Express Scripts FTC Changes could translate into “up to $7 billion” in reduced out-of-pocket drug costs for patients over the next 10 years.

At the heart of the dispute was a pricing structure critics likened to a hall of mirrors — list prices rising ever higher while rebates flowed behind the scenes. Regulators argued that those rebate arrangements inflated insulin costs, leaving patients to shoulder bills tied to artificially elevated sticker prices.

From List Prices to Net Prices

“For years, out-of-pocket costs for patients were driven by artificially high list prices and convoluted rebate games,” FTC Chairman Andrew Ferguson wrote in a post on X. “That ends with this settlement. Now, out-of-pocket costs for American patients will now be set by net drug prices.”

In essence, the settlement shifts the benchmark for what patients pay. Instead of calculating costs based on inflated list prices, the framework would tie out-of-pocket expenses to net prices — the amounts after rebates and discounts are accounted for.

A Narrow Vote at the Commission

The decision to approve the settlement came from a sharply divided and diminished commission. With Commissioner Mark Meador recused, Ferguson cast the sole vote in favor of the deal. The FTC currently operates with only two members, both Republicans.

The settlement removes Express Scripts from the agency’s ongoing administrative case but leaves Caremark Rx and OptumRx still facing allegations that they participated in rebate practices that pushed insulin prices higher.

Fallout and the Road Ahead

The Express Scripts FTC Changes land at a time of intensifying scrutiny over prescription drug pricing, particularly for insulin, a medication millions of Americans depend on daily.

By stepping away from the legal fray, Express Scripts avoids further litigation while committing to structural adjustments regulators say could recalibrate how drug benefits are priced nationwide.

Whether the promised billions in savings materialize — and whether the remaining cases against other PBMs reshape the broader market — now becomes the next chapter in a battle that has turned complex rebate systems into a national flashpoint.